Respiration · 2014 · 25 citations · 35 references
MedicineBiochemistryPharmacologyInflammationLipid BiochemistryPulmonologyChronic Obstructive Pulmonary DiseaseEicosanoid BiosynthesisObstructive Lung DiseasePulmonary InflammationRespiratory DiseaseRespiratory PathophysiologyAirway Inflammation CorrelatesChronic Obstructive Pulmonary Disease InflammationChronic Obstructive Pulmonary Disease PathophysiologyCysteinyl Leukotriene PathwayInflammatory Mediators Derived From EicosanoidsLeukotriene BiosynthesisLeukotriene MediatorsPulmonary Exacerbations
<b><i>Background:</i></b> Eicosanoids are small lipid molecules with diverse biological functions in the airways. <b><i>Objectives:</i></b> The aim of this study was to investigate changes in leukotriene B<sub>4</sub> (LTB<sub>4</sub>), 8-isoprostane, prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and cysteinyl-leukotriene (cys-LT) levels in the sputum of patients with chronic obstructive pulmonary disease (COPD) at the onset of a severe exacerbation and during the course of recovery. <b><i>Methods:</i></b> Thirty-seven ex-smoker COPD patients suffering an episode of acute exacerbation were enrolled. Samples were taken (i) on hospital admission and (ii) after regular treatment. Twenty-five stable ex-smoker COPD patients served as controls. Eicosanoids were determined by enzyme immunoassay. <b><i>Results:</i></b> Sputum PGE<sub>2</sub> [39.8 (13.3-103.3) vs. 5.05 (2.3-12.1) pg/ml, p < 0.001], 8-isoprostane [89.5 (36.9-184.7) vs. 29.7 (13.8-68.8) pg/ml, p < 0.01] and LTB<sub>4</sub> [587.7 (252.9-774.8) vs. 276.1 (105.4-594.7) pg/ml, p < 0.05] levels were increased in patients with exacerbation compared to stable subjects. After treatment only PGE<sub>2</sub> levels decreased significantly [at discharge: 19.6 (4.6-52.5) pg/ml, p < 0.01], the levels of other eicosanoids remained elevated (p = NS). Sputum cys-LT levels were similar in stable patients and in those with exacerbation and treatment did not influence cys-LTs either. There was a significant correlation between PGE<sub>2</sub> and sputum neutrophil and lymphocyte cell counts in patients with exacerbation. <b><i>Conclusions:</i></b> Our results suggest that 8-isoprostane, LTB<sub>4</sub> and PGE<sub>2</sub> but not cys-LTs may be involved in exacerbation-associated inflammatory processes in the airways of patients with COPD. Validation of PGE<sub>2</sub> for use as a biomarker of recovery from an exacerbation requires further studies.
35
Paolo Montuschi, John V. Collins, Giovanni Ciabattoni et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 547 citations
P. N. Richard Dekhuijzen, Katja K.H. Aben, Irene Dekker et al. · American Journal of Respiratory and Critical Care Medicine · 1996 · 509 citations
Exhaled leukotrienes and prostaglandins in COPD
Paolo Montuschi · Thorax · 2003 · 292 citations · Full text